Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Yttrium-90 × Endocrine × Clear all

Phase

Phase NA 1 Phase 2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 4 Sarcoma 1 NET 1 Endocrine 1

Conditions

Neuroendocrine Tumors 1

Interventions

Everolimus 25 lutetium Lu 177 dotatate 21 Temozolomide 20 pembrolizumab 19 Cisplatin 14 lenvatinib 13 Magnetic Resonance Spectroscopy 13 Capecitabine 13 Sunitinib 12 Nivolumab 12 cabozantinib 11 Specimen Handling 11 Bevacizumab 11 Sorafenib 9 Etoposide 9 trametinib 8 dabrafenib 8 pasireotide 7 lanreotide 7 Paclitaxel 7 Octreotide 7 Ipilimumab 7 Carboplatin 7 pazopanib 6 Irinotecan 6 gallium Ga 68 dotatate 5 Mitotane 5 Injections 5 Fluorodeoxyglucose F18 5 surufatinib 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04339036 2025-12-10

CapTemY90

Abramson Cancer Center at Penn Medicine

Phase 2 Recruiting

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡